Fiche publication
Date publication
juillet 2026
Journal
American journal of hematology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEBLIQUIS Agathe
,
Dr DRENOU Bernard
Tous les auteurs :
Wagner-Ballon O, Lhoumeau AC, Raimbault A, Debord C, Vial JP, Soenen V, Pannetier M, Bonneville E, Bera E, Bret C, Chapuis N, Latger-Cannard V, Mayeur-Rousse C, Harrivel V, Vergez F, Loosveld M, Xuan JV, Mathis S, Socié G, de Fontbrune FS, de Latour RP, Drenou B, Debliquis A, Le Garff-Tavernier M,
Lien Pubmed
Résumé
The clinical significance of PNH Type II white blood cells (WBCs) remains unclear. We assessed the relative percentage (rel%) of Type II neutrophils in 355 patients with a PNH clone ≥ 1% on neutrophils enrolled by 33 flow cytometry laboratories in the 5-year French nation-wide multicenter prospective observational study. We first analyzed 127 of 133 patients with a major PNH clone (≥ 50%) and evaluable Type II neutrophil rel%. Using hemolysis data available for 107 patients, a threshold of 3% Type II neutrophils rel% distinguished two groups: 22 "high Type II" and 105 "low Type II" patients. Hemolysis was less frequent in the "high Type II" group. Thrombosis was more frequent at diagnosis and during cumulative long-term follow-up in this group. High neutrophil rel% ≥ 3% was independently associated with thrombotic events. Among 222 patients with smaller PNH clones (1%-50%), 207 displayed evaluable Type II neutrophil rel%, of which 87 were classified as "high Type II" and 120 as "low Type II". Although no thrombosis was present at diagnosis, two thrombotic events occurred during follow-up in the "high Type II" group, whereas none were observed in the "low Type II" group. Long-term follow-up showed no major changes in Type II neutrophil rel%, irrespective of variations in total clone size. These findings suggest that, regardless of the total PNH clone size, PNH Type II neutrophil rel% is a stable parameter and may represent a reliable predictor of thrombosis, potentially supporting earlier consideration of anticomplement therapy initiation.
Référence
Am J Hematol. 2026 07 3;:
